title: New oral anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study.
abstract: OBJECTIVE
  Atrial flutter (AFL) ablation requires optimal periprocedural anticoagulation in order to minimize thromboembolic events/bleeding risk. This study describes the characteristics of patients receiving new oral anticoagulants before AFL ablation and assesses complications.
  
  
  METHODS
  This multicenter, retrospective study reports ischemic and hemorrhagic predischarge, postprocedural complications.
  
  
  RESULTS
  We evaluated 60 patients (62.3% male; mean age: 69.2 ± 9.7 years; CHA2DS2-VASc score: 2.44 ± 1.46, HAS-BLED score: 1.14 ± 0.7). Twenty-one (35.0%) and 23 patients (38.3%) received twice-daily dabigatran 110 or 150 mg; 16 patients (26.6%) received once-daily rivaroxaban (15 mg [n = 5] or 20 mg [n = 11]). Four cases of postprocedural minor bleeding were reported.
  
  
  CONCLUSIONS
  This is the first study assessing new oral anticoagulants for periprocedural anticoagulation, specifically in patients undergoing AFL ablation. No major bleeding was reported. Further prospective investigation is warranted.
authors.affiliation: Cardiology Department, GHI Le Raincy-Montfermeil, 10 rue du GL Leclerc, 93370 Montfermeil, France.
authors.forename: Walid
authors.initials: W
authors.lastname: Amara
authors.forename: Stéphane
authors.initials: S
authors.lastname: Fromentin
authors.forename: Antoine
authors.initials: A
authors.lastname: Dompnier
authors.forename: Cédric
authors.initials: C
authors.lastname: Nguyen
authors.forename: Emna
authors.initials: E
authors.lastname: Allouche
authors.forename: Jérôme
authors.initials: J
authors.lastname: Taieb
authors.forename: Frédéric
authors.initials: F
authors.lastname: Georger
authors.forename: Nadir
authors.initials: N
authors.lastname: Saoudi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000628:therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D017115:Catheter Ablation; D000069604:Dabigatran; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010865:Pilot Projects; D012189:Retrospective Studies; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: atrial flutter; dabigatran; new oral anticoagulants; radiofrequency ablation; rivaroxaban; stroke